Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2005-06-21
2005-06-21
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S204100, C435S069100, C435S069700, C530S300000
Reexamination Certificate
active
06908613
ABSTRACT:
Disclosed are chimeric HPV L1 proteins and virus like particles comprising the same which are capable of generating high titer neutralizing antibody responses against at least two HPV types. The disclosed chimeric HPV L1 proteins and VLPs are useful as therapeutic and prophylactic reagents, as well as reagents for diagnosing papillomavirus infection.
REFERENCES:
patent: 5618536 (1997-04-01), Lowy et al.
patent: 5855891 (1999-01-01), Lowy et al.
patent: 6066324 (2000-05-01), Gissmann et al.
patent: WO 96/11272 (1996-04-01), None
patent: WO 99/18220 (1999-04-01), None
Steller M. A. , Current Opinion in Investigational Drugs, 2002, vol. 3, No. 1, pp. 37-47.
Zhang, et al., “HPV6b virus like particles are potent immunogens without adjuvant in man”,Vaccine18 (2000), 1051-1058.
Mullikin Brian
Suzich JoAnn
White Wendy
Wilson Susan D.
Lillie Raymond J.
MedImmune, Inc.
Olstein Elliot M.
Salimi Ali R.
LandOfFree
Chimeric human papillomavirus (HPV) L1 molecules and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric human papillomavirus (HPV) L1 molecules and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric human papillomavirus (HPV) L1 molecules and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3490115